Fluvoxamine prevents recurrence of depression: Results of a long-term, double-blind, placebo-controlled study

International Clinical Psychopharmacology

Volumn 13, Issue 2, 1998, Pages 55-62

  Terra, J L ^a   Montgomery, S A ^b  

^a CENTRE HOSPITALIER LE VINATIER   (France)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Depression; Fluvoxamine; Long term treatment; Maintenance; Prophylaxis; Recurrence

Indexed keywords

FLUVOXAMINE;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; SOMNOLENCE; VOMITING;

EID: 0031971040     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199803000-00001     Document Type: Article

References (38)

1. Angst J. (1992). How recurrent and predictable is depressive illness? In: Montgomery SA, Rouillon F, editors. Long-term treatment of depression. Chichester: Wiley; pp. 1-14.
2. Anton SF, Robinson DS, Roberts DL, Kensler TT, English PA, Archibald DG (1994). Long-term treatment of depression with nefazodone. Psychopharmacol Bull 30:165-169.
3. Bjork K (1983). The effect of zimelidine in preventing depressive episodes in recurrent depressive disorders - a double blind placebo controlled study. Acta Psychiatr Scand 68 (suppl. 308):182-189.
4. CINP Task Force (1993). Impact of neuropharmacology in the 1990s - strategies for the therapy of depressive illness. Eur Neuropsychopharmacol 3:153-156.
5. Consensus Development Panel (1985). NIMH/NIH Consensus Development Conference Statement: Mood disorders: pharmacologic prevention of recurrences. Am J Psychiatry 142:469-477.
6. Coppen A, Ghose K, Montgomery SA, Rao AV, Bailey J, Jorgensen A (1978). Continuation therapy with amitriptyline in depression. Br J Psychiatry 133:28-33.
7. Covi L, Rickels K, Lipman OS, McNair DM, Smith VK, Downing R et al. (1981). Effects of psychotropic agents on primary depression. Psychopharmacol Bull 17:100-103.
8. Doogan DP, Caillard V (1992). Sentraline in the prevention of depression. Br J Psychiatry 160:217-222.
9. Feldman HS, Denber HCB (1982). Long-term study of fluvoxamine: a new rapid acting antidepressant. Int Clin Psychopharmacol 17:114-122.
10. Franchini L, Gasperini M, Smeraldi E. (1994). A 24-month follow-up study of unipolar subjects: a comparison between lithium and fluvoxamine. J Affect Dis 32:225-231.
11. Frank E, Kupfer DJ, Perel JM, Comes C, Jarrett DB, Mallinger AG et al. (1990). Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 47:1093-1099.
12. Frank E, Kupfer DJ, Perel JM, Comes C, Mallinger AG, Thase ME et al. (1993). Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disdord 27:139-145.
13. Georgotas A, McCue RE, Cooper TB (1989). A placebo controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients. Arch Gen Psychiatry 46:783-786.
14. Guelfi JD, Dreyfus JF, Pichot P and GEPECEP (1983). A double-blind controlled clinical trial comparing fluvoxamine with imipramine. Br J Clin Pharmacol 15 (suppl. 3):411S-417S.
15. Hamilton M (1960). A rating scale for depression. J Neurolog Neurosurg Psychiatry 23:56-62.
16. Hirschfeld RMA (1994). Long-term management of depression. Am J Psychiatry 97 (suppl. 6A):33-38.
17. Kasper S, Moller HJ, Montgomery SA, Zonday B (1995). Antidepressant efficacy in relation to item analysis and severity of depression: a placebo-controlled trial of fluvoxamine versus imipramine. Int Clin Psychopharmacol 9 (suppl. 4):3-12.
18. Keller MB, Lavori PW, Mueller TI, Endicott J, Coryell WS, Hirschfeld RMA, Shea MT (1992). Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 49:809-816.
19. Kupfer DJ (1991). Long-term treatment of depression. J Clin Psychiatry 52 (suppl.):28-34.
20. Kupfer DJ, Frank E, Perel JM, Comes C, Mallinger AG, Thase ME et al. (1992). Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 49:769-773.
21. Martin AJ, Wakelin J (1986). Fluvoxamine - a baseline study of clinical response, long-term tolerance and safety in a general practice population. Br J Clin Practice 40:95-99.
22. Mindham RHS, Rowland C, Shepherd M (1973). An evaluation of continuation therapy with tricyclic antidepressants in depressive illness. Psychol Med 3:5-17.
23. Montgomery SA (1989). Prophylaxis in recurrent unipolar depression: a new indication for treatment studies. J Psychopharmacol 3 (suppl. 2):47-53.
24. Montgomery SA (1995). Selective serotonin reuptake inhibitors in the acute treatment of depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology, the fourth generation of progress. New York: Raven Press; pp. 1043-1051.
25. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
26. Montgomery SA, Dunbar GC (1993). Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 8:189-195.
27. Montgomery SA, Dufour H, Brion S, Gailledreau J, Lequeille X, Ferrey G et al. (1988). The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 153 (suppl. 3):69-76.
28. Montgomery SA, Bebbington PE, Cowen P, Deakin W, Freeling P, Hallstrom C et al. (1993a). Guidelines for treating depressive illness with antidepressants. J Psychopharmacol 7:19-23.
29. Montgomery SA, Rasmussen JGC, Tanghoj P (1993b). A 24 week study of 20 mg citalopram, 40 mg citalopram and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 8:181-188.
30. Nystrom S (1979). Depression: factors related to 10 year prognosis. Acta Psychiatr Scand 60:225-238.
31. Prien RF, Kupfer DJ (1986). Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry 143:18-23.
32. Prien RF, Klett CJ, Caffey EM (1973). Lithium carbonate and imipramine in the prevention of affective episodes. Arch Gen Psychiatry 29:420-425.
33. Prien RF, Kupfer DJ, Manskey PA, Small JG, Tuasou VB, Voss C, Johnson WE (1984). Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine and a lithium carbonate-imipramine carbonate combination. Arch Gen Psychiatry 41:1096-1104.
34. Wagner W, Zaborny BA, Gray TE (1994). Fluvoxamine. A review of its safety profile in worldwide studies. Int Clin Psychopharmacol 9:222-226.
35. Wagner W, Rouser V, Wong LF (1996). The safety profile of fluvoxamine in elderly patients. Int Clin Psychopharmacol 11:267-272.
36. Wakelin JS (1986). Fluvoxamine in the treatment of the older depressed patient: double blind placebo controlled data. Int Clin Psychopharmacol 1:221-230.
37. Wilde MI, Benfield P (1993). Fluvoxamine: an updated review of its pharmacology and therapeutic use in depressive illness. Drugs 46:895-924.
38. Zis AP, Goodwin FK (1979). Major affective disorder as a recurrent illness: a critical review. Arch Gen Psychiatry 36:835-839.